Cargando…
Risk of colorectal cancer for carriers of a germline mutation in POLE or POLD1
BACKGROUND: Germline mutations in the exonuclease domains of the POLE and POLD1 genes are associated with an as yet unquantified increased risk of colorectal cancer (CRC). METHODS: We identified families with POLE or POLD1 variants by searching PubMed for relevant studies prior to October 2016 and b...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943186/ https://www.ncbi.nlm.nih.gov/pubmed/29120461 http://dx.doi.org/10.1038/gim.2017.185 |
_version_ | 1783321579390763008 |
---|---|
author | Buchanan, Daniel D. Stewart, Jenna R. Clendenning, Mark Rosty, Christophe Mahmood, Khalid Pope, Bernard J. Jenkins, Mark A. Hopper, John L. Southey, Melissa C. Macrae, Finlay A. Winship, Ingrid M. Win, Aung Ko |
author_facet | Buchanan, Daniel D. Stewart, Jenna R. Clendenning, Mark Rosty, Christophe Mahmood, Khalid Pope, Bernard J. Jenkins, Mark A. Hopper, John L. Southey, Melissa C. Macrae, Finlay A. Winship, Ingrid M. Win, Aung Ko |
author_sort | Buchanan, Daniel D. |
collection | PubMed |
description | BACKGROUND: Germline mutations in the exonuclease domains of the POLE and POLD1 genes are associated with an as yet unquantified increased risk of colorectal cancer (CRC). METHODS: We identified families with POLE or POLD1 variants by searching PubMed for relevant studies prior to October 2016 and by genotyping 669 population-based CRC cases diagnosed <60 years of age from the Australasian Colorectal Cancer Family Registry. We estimated the age-specific cumulative risks (penetrance) using a modified segregation analysis. RESULTS: We observed 67 CRCs (mean age at diagnosis=50.2 (standard deviation [SD]=13.8) years) among 364 first- and second- degree relatives from 41 POLE families and 6 CRCs (mean age at diagnosis=39.7 (SD=6.83) years) among 69 relatives from 9 POLD1 families. We estimated risks of CRC to age 70 years (95% confidence interval [CI]) for males and females, respectively, to be: 40%(26%–57%) and 32%(20%–47%) for POLE mutation carriers; and 63%(15%–99%) and 52%(11%–99%) for POLD1 mutation carriers. CONCLUSION: CRC risks for POLE mutation carriers are sufficiently high warranting consideration of annual colonoscopy screening and management guidelines comparable to Lynch syndrome. Refinement of estimates of CRC risk for POLD1 carriers is needed, however, clinical management recommendations could follow those suggested for POLE carriers. |
format | Online Article Text |
id | pubmed-5943186 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
record_format | MEDLINE/PubMed |
spelling | pubmed-59431862018-09-21 Risk of colorectal cancer for carriers of a germline mutation in POLE or POLD1 Buchanan, Daniel D. Stewart, Jenna R. Clendenning, Mark Rosty, Christophe Mahmood, Khalid Pope, Bernard J. Jenkins, Mark A. Hopper, John L. Southey, Melissa C. Macrae, Finlay A. Winship, Ingrid M. Win, Aung Ko Genet Med Article BACKGROUND: Germline mutations in the exonuclease domains of the POLE and POLD1 genes are associated with an as yet unquantified increased risk of colorectal cancer (CRC). METHODS: We identified families with POLE or POLD1 variants by searching PubMed for relevant studies prior to October 2016 and by genotyping 669 population-based CRC cases diagnosed <60 years of age from the Australasian Colorectal Cancer Family Registry. We estimated the age-specific cumulative risks (penetrance) using a modified segregation analysis. RESULTS: We observed 67 CRCs (mean age at diagnosis=50.2 (standard deviation [SD]=13.8) years) among 364 first- and second- degree relatives from 41 POLE families and 6 CRCs (mean age at diagnosis=39.7 (SD=6.83) years) among 69 relatives from 9 POLD1 families. We estimated risks of CRC to age 70 years (95% confidence interval [CI]) for males and females, respectively, to be: 40%(26%–57%) and 32%(20%–47%) for POLE mutation carriers; and 63%(15%–99%) and 52%(11%–99%) for POLD1 mutation carriers. CONCLUSION: CRC risks for POLE mutation carriers are sufficiently high warranting consideration of annual colonoscopy screening and management guidelines comparable to Lynch syndrome. Refinement of estimates of CRC risk for POLD1 carriers is needed, however, clinical management recommendations could follow those suggested for POLE carriers. 2017-11-09 2018-08 /pmc/articles/PMC5943186/ /pubmed/29120461 http://dx.doi.org/10.1038/gim.2017.185 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Buchanan, Daniel D. Stewart, Jenna R. Clendenning, Mark Rosty, Christophe Mahmood, Khalid Pope, Bernard J. Jenkins, Mark A. Hopper, John L. Southey, Melissa C. Macrae, Finlay A. Winship, Ingrid M. Win, Aung Ko Risk of colorectal cancer for carriers of a germline mutation in POLE or POLD1 |
title | Risk of colorectal cancer for carriers of a germline mutation in POLE or POLD1 |
title_full | Risk of colorectal cancer for carriers of a germline mutation in POLE or POLD1 |
title_fullStr | Risk of colorectal cancer for carriers of a germline mutation in POLE or POLD1 |
title_full_unstemmed | Risk of colorectal cancer for carriers of a germline mutation in POLE or POLD1 |
title_short | Risk of colorectal cancer for carriers of a germline mutation in POLE or POLD1 |
title_sort | risk of colorectal cancer for carriers of a germline mutation in pole or pold1 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943186/ https://www.ncbi.nlm.nih.gov/pubmed/29120461 http://dx.doi.org/10.1038/gim.2017.185 |
work_keys_str_mv | AT buchanandanield riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1 AT stewartjennar riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1 AT clendenningmark riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1 AT rostychristophe riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1 AT mahmoodkhalid riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1 AT popebernardj riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1 AT jenkinsmarka riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1 AT hopperjohnl riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1 AT southeymelissac riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1 AT macraefinlaya riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1 AT winshipingridm riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1 AT winaungko riskofcolorectalcancerforcarriersofagermlinemutationinpoleorpold1 |